WO2006055511A3 - Stable tablet formulation of tetrahydrobiopterin - Google Patents

Stable tablet formulation of tetrahydrobiopterin Download PDF

Info

Publication number
WO2006055511A3
WO2006055511A3 PCT/US2005/041252 US2005041252W WO2006055511A3 WO 2006055511 A3 WO2006055511 A3 WO 2006055511A3 US 2005041252 W US2005041252 W US 2005041252W WO 2006055511 A3 WO2006055511 A3 WO 2006055511A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydrobiopterin
tablet formulation
stable tablet
stable
formulations
Prior art date
Application number
PCT/US2005/041252
Other languages
French (fr)
Other versions
WO2006055511A2 (en
Inventor
Steven Jungles
Mark Henderson
Victoria Sluzky
Robert Baffi
Original Assignee
Biomarin Pharm Inc
Steven Jungles
Mark Henderson
Victoria Sluzky
Robert Baffi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35849290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006055511(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0517088-5A priority Critical patent/BRPI0517088A/en
Priority to JP2007541419A priority patent/JP2008520574A/en
Priority to MX2007005039A priority patent/MX2007005039A/en
Priority to CA2581814A priority patent/CA2581814C/en
Priority to AU2005306686A priority patent/AU2005306686B2/en
Application filed by Biomarin Pharm Inc, Steven Jungles, Mark Henderson, Victoria Sluzky, Robert Baffi filed Critical Biomarin Pharm Inc
Priority to EP05822282A priority patent/EP1845952A2/en
Priority to US10/563,418 priority patent/US8003126B2/en
Publication of WO2006055511A2 publication Critical patent/WO2006055511A2/en
Publication of WO2006055511A3 publication Critical patent/WO2006055511A3/en
Priority to IL182161A priority patent/IL182161A/en
Priority to US12/106,621 priority patent/US7566462B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.
PCT/US2005/041252 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin WO2006055511A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/563,418 US8003126B2 (en) 2004-11-17 2005-11-16 Stable tablet formulation
JP2007541419A JP2008520574A (en) 2004-11-17 2005-11-16 Tetrahydrobiopterin stable tablet formulation
MX2007005039A MX2007005039A (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin.
CA2581814A CA2581814C (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin
AU2005306686A AU2005306686B2 (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin
BRPI0517088-5A BRPI0517088A (en) 2004-11-17 2005-11-16 stable tablet formulation
EP05822282A EP1845952A2 (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin
IL182161A IL182161A (en) 2004-11-17 2007-03-25 Stable formulation comprising a crystalline polymorph of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US12/106,621 US7566462B2 (en) 2004-11-17 2008-04-21 Stable tablet formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62918904P 2004-11-17 2004-11-17
US60/629,189 2004-11-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/563,418 A-371-Of-International US8003126B2 (en) 2004-11-17 2005-11-16 Stable tablet formulation
US12/106,621 Continuation US7566462B2 (en) 2004-11-17 2008-04-21 Stable tablet formulation

Publications (2)

Publication Number Publication Date
WO2006055511A2 WO2006055511A2 (en) 2006-05-26
WO2006055511A3 true WO2006055511A3 (en) 2006-10-05

Family

ID=35849290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041252 WO2006055511A2 (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin

Country Status (15)

Country Link
US (2) US8003126B2 (en)
EP (2) EP1845952A2 (en)
JP (2) JP2008520574A (en)
KR (1) KR20070084270A (en)
CN (1) CN101132776A (en)
AR (1) AR052238A1 (en)
AU (1) AU2005306686B2 (en)
BR (1) BRPI0517088A (en)
CA (1) CA2581814C (en)
IL (1) IL182161A (en)
MX (1) MX2007005039A (en)
MY (1) MY142120A (en)
PE (1) PE20061294A1 (en)
TW (1) TW200624120A (en)
WO (1) WO2006055511A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
WO2005107759A1 (en) * 2004-05-11 2005-11-17 Daiichi Asubo Pharma Co., Ltd. Bh4-responsive hyperphenylalaninemia remedies
KR20070084270A (en) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. Stable tablet formulation
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
JP2010515747A (en) * 2007-01-12 2010-05-13 ビオマリン プハルマセウトイカル インコーポレイテッド Tetrahydrobiopterin prodrug
DE22154751T1 (en) 2007-04-11 2022-09-08 Biomarin Pharmaceutical Inc. TETRAHYDROBIOPTERIN FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF PHENYLALANIN
ECSP077628A (en) * 2007-05-03 2008-12-30 Smithkline Beechman Corp NEW PHARMACEUTICAL COMPOSITION
AU2008347005B2 (en) * 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
ES2736730T3 (en) * 2008-08-12 2020-01-07 Orpha Swiss Gmbh Pharmaceutical administration form containing tetrahydrobiopterin
CN103458900A (en) * 2011-03-01 2013-12-18 鲁必康研究私人有限公司 Stable compositions of tetrahydrobiopterin
WO2012127431A1 (en) * 2011-03-24 2012-09-27 Rubicon Research Private Limited Stabilized compositions of tetrahydrobiopterin
CN104530051B (en) * 2012-01-20 2016-08-24 连云港金康和信药业有限公司 Stable (6R, S)-5-methyltetrahydrofolate crystal formation and preparation method thereof
CN102775408B (en) * 2012-01-20 2015-09-02 连云港金康医药科技有限公司 Stable 5-methyltetrahydrofolate crystal formation and preparation method thereof
PT2926805T (en) 2014-03-31 2016-07-15 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2017106130A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions
CN108366921A (en) * 2015-12-18 2018-08-03 高露洁-棕榄公司 Instant capacity permonosulphuric acid salt composite
KR20230161535A (en) 2016-07-26 2023-11-27 바이오마린 파머수티컬 인크. Novel adeno-associated virus capsid proteins
EP3490536A1 (en) 2016-07-29 2019-06-05 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
US20180110781A1 (en) * 2016-10-24 2018-04-26 Research Foundation For Mental Hygiene, Inc. System and method for diagnosis and treatment of neuropsychiatric disorders
US10758462B2 (en) * 2016-11-16 2020-09-01 Colgate-Palmolive Company Oral care composition
BR122021026889A8 (en) * 2016-11-29 2022-11-22 Censa Pharmaceuticals Inc FREE BASE CRYSTALLINE FORMS OF SEPIAPTERIN AND SALTS THEREOF, THEIR METHOD OF PREPARATION, COMPOSITIONS THAT COMPRISE THEM, USE OF THEM AND METHOD OF PREPARATION OF A LIQUID FORMULATION
CA3043499A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
MX2020002271A (en) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Pharmaceutical compositions comprising sepiapterin and uses thereof.
KR20210008501A (en) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. How to treat phenylketonuria
TW202005978A (en) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 Novel liver targeting adeno-associated viral vectors
MX2020012979A (en) 2018-05-30 2021-04-29 Ptc Therapeutics Mp Inc Methods for increasing sepiapterin plasma exposure.
TR201914420A2 (en) * 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE ANTIOXIDANT
TR201914406A2 (en) * 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT
TW202144575A (en) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 Treatment of phenylketonuria with aav and therapeutic formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63267781A (en) * 1987-04-24 1988-11-04 Suntory Ltd Remedy for ameliorating neutral symptom accompanying to malignant tumor and grave viral infection
EP0906913A1 (en) * 1997-10-06 1999-04-07 Ernst Werner Pteridinderivatives as NO synthase inhibitors
WO2005065018A2 (en) * 2003-11-17 2005-07-21 Merck Eprova Ag Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2603643A (en) 1947-03-13 1952-07-15 Hoffmann La Roche 2-amino-4-hydroxy-6-polyhydroxyalkyl pteridine and methods of oxidizing same
US2601215A (en) 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US2541717A (en) 1948-10-18 1951-02-13 Upjohn Co Pterine imines
US2568685A (en) 1950-07-22 1951-09-18 Upjohn Co 2-amino-4-hydroxy-6-omega-carboxytrihydroxy-propylpteridines
US2955110A (en) 1955-01-13 1960-10-04 American Cyanamid Co Substituted pteridines and method of preparing the same
US3505329A (en) 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
GB2056459B (en) 1979-07-04 1983-03-09 Daiichi Radioisotope Lab Pterin derivatives and an assay method for determining pterins
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
JPS5883691A (en) 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd 1',2'-diacyl-(6r,s)-5,6,7,8-tetrahydro-l-biopterin and its preparation
JPS5925323A (en) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 Depression disease parkinsonism therapy made from pterin derivative
JPS5921685A (en) 1982-07-28 1984-02-03 Suntory Ltd Preparation of tetrahydro-l-biopterin
GB8318833D0 (en) 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
EP0108890B1 (en) 1982-09-20 1988-12-07 The Wellcome Foundation Limited Pharmaceutically active pteridine derivatives
JPS5976086A (en) 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド Pteridine compound
US5196533A (en) 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (en) 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd Preparation of 5,6,7,8-tetrahydro-l-biopterin
JPS60199889A (en) 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd 5,6,7,8-tetrahydro-l-erythro-biopterin sulfate and its preparation
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
DE3437944A1 (en) 1984-10-17 1986-07-31 Biotest-Serum-Institut Gmbh, 6000 Frankfurt USE OF PTERINES TO INCREASE THE ACTIVITY OF LYMPHOKINES AND OTHER BLOOD FACTORS, AND A DIAGNOSTIC OR THERAPEUTIC PREPARATION CONTAINING PTERINE IN COMBINATION WITH LYMPHOKINES
JPS61172877A (en) * 1985-01-28 1986-08-04 Shiratori Seiyaku Kk Production of (6r)-tetrahydro-l-biopterin
US4713454A (en) 1985-01-28 1987-12-15 Shiratori Pharmaceutical Co., Ltd. Preparation process of (6R)-tetrahydro-L-biopterin
JPS61277618A (en) 1985-06-04 1986-12-08 Suntory Ltd Remedy for autism
DE3772193D1 (en) 1987-02-13 1991-09-19 Allergan Pharma USE OF PTERIDINES AND / OR PURINES OR A XANTHINOXIDASE INHIBITOR FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF GENETICALLY DEGENERATIVE NET SKIN DISEASES.
US4937342A (en) 1987-11-30 1990-06-26 Kabushiki Kaisha Vitamin Kenkyusyo Intermediates for synthesizing BH4 and its derivatives
EP0349204A3 (en) 1988-06-28 1991-08-07 Bend Research, Inc. Use and regeneration of reagents using coupled reactions and permselective barriers
JP2843592B2 (en) 1989-02-28 1999-01-06 日清製粉株式会社 L-ribose derivative
US5554647A (en) 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
WO1991012814A1 (en) 1990-02-28 1991-09-05 E.I. Du Pont De Nemours And Company Activation of monocyte/macrophages
JP3137333B2 (en) 1990-07-21 2001-02-19 サントリー株式会社 Method for producing tetrahydrobiopterin and enzyme used therefor
DE4037447C2 (en) 1990-11-24 1994-06-01 Milupa Ag Phenylalanine-free dietetic for juvenile and adult individuals with phenylketonuria and a method for its production
JPH04210624A (en) 1990-12-11 1992-07-31 Shigenobu Sakata Bathing agent and lotion having medicinal effect
EP0592673B1 (en) 1991-11-16 1999-05-26 Suntory Limited 6(r)-l-erythro-5,6,7,8-tetrahydrobiopterin receptor
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
JP2534423B2 (en) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド Inhibitors that prevent vascular disorders resulting from overproduction of nitric oxide
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
DE4215275A1 (en) 1992-05-09 1993-11-11 Merck Patent Gmbh Means and methods for the treatment of body fluids in the determination of neopterin
US6251953B1 (en) 1992-10-30 2001-06-26 Andrew Brookner Beta-carotene therapy of individuals having abnormal immunological and serological indices, and individuals having infections and diseases causing changes therein
US5658565A (en) 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5830461A (en) 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
EP0670902A1 (en) 1992-11-25 1995-09-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education cDNA CLONE FOR HUMAN INDUCIBLE NITRIC OXYDE SYNTHASE AND PROCESS FOR PREPARING SAME
US20020061862A1 (en) 1992-11-25 2002-05-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase for treatment of disease
US5468772A (en) 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
DE69431620T2 (en) 1993-03-19 2003-07-03 Vacsyn Sa COMPOSITIONS FOR USE IN HUMAN THERAPY, CHARACTERIZED BY ASSOCIATING A MURAMYL PEPTIDE WITH A CYTOKIN
DE4308739C1 (en) 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterin derivatives, their preparation and their use
US5449688A (en) 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
US5945452A (en) 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
TW282398B (en) 1993-12-22 1996-08-01 Bristol Myers Squibb Co
JP3347870B2 (en) * 1994-04-15 2002-11-20 三菱電機株式会社 Superconducting magnet and regenerative refrigerator for the magnet
DE4418096A1 (en) 1994-05-24 1995-11-30 Cassella Ag Use of pteridine derivatives as inhibitors of NO synthase
DE69526918T2 (en) 1994-08-05 2002-12-19 Suntory Ltd MEDICINE AGAINST SPINOCEREBELLAR DEGENERATION
US5643586A (en) 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
US5744340A (en) 1995-06-09 1998-04-28 Schering Corporation Expression of human inducible nitric oxide synthase
SE506533C2 (en) 1995-07-03 1998-01-12 Birger Andersson A process for in vitro analysis of the toxic and allergenic properties of substances and the use of neopterin to distinguish between allergic immune reactions
US5879690A (en) 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
JP2711828B2 (en) 1996-06-25 1998-02-10 白鳥製薬株式会社 Method for producing (6R) -tetrahydro-L-biopterin hydrochloride
US5856158A (en) 1996-07-05 1999-01-05 University Of Iowa Research Foundation Purified nitric oxide synthase from rat brain
US20020076782A1 (en) 1996-07-05 2002-06-20 John P.N. Rosazza Purified nitric oxide synthase
WO1998004558A1 (en) 1996-07-31 1998-02-05 Artemis, Inc. Active oxygen scavengers containing pterin derivatives
GB9617990D0 (en) 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0908182B2 (en) 1996-08-30 2007-03-28 Daiichi Asubio Pharma Co., Ltd. Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos)
WO1998028298A1 (en) 1996-12-24 1998-07-02 Research Development Foundation Ricin inhibitors and methods for use thereof
US6562969B1 (en) 1996-12-24 2003-05-13 Research Development Foundation Ricin inhibitors and methods for use thereof
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
US5846775A (en) 1997-04-22 1998-12-08 Incyte Pharmaceuticals, Inc. GTP cyclohydrolase I regulatory protein
CH693255A5 (en) 1997-06-13 2003-05-15 Eprova Ag Use of tetrahydrofolates natürlichenstereoisomeren in the form suitable for the preparation of a pharmaceutical composition for influencing the homocysteine ​​level.
US5922713A (en) 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
AU1189399A (en) 1997-10-15 1999-05-03 Uab Research Foundation Bathocuproine treatment of neurologic disease
ES2242381T3 (en) 1998-02-27 2005-11-01 Daiichi Suntory Pharma Co., Ltd. PROPHLACTIC AGENTS OR REMEDIES AGAINST RENAL DISORDERS OF MEDICINAL ORIGIN.
JP4306825B2 (en) 1998-02-27 2009-08-05 アスビオファーマ株式会社 Preventive or therapeutic agent for diseases associated with vascular dysfunction involving insulin resistance
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
US6162914A (en) 1998-04-24 2000-12-19 Cerbios-Pharma S.A. Process for the reduction of pterins
US6117872A (en) 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6656925B2 (en) 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
US6346519B1 (en) 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
CN1555264A (en) 1999-01-08 2004-12-15 3M Formulations for treatment of mucosal associated conditions with an immune response modifier
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
JP2002539257A (en) 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド Increased drug bioavailability in the brain
US6288535B1 (en) 1999-07-06 2001-09-11 Jacob Chass Hall effect, shaft angular position sensor with asymmetrical rotor
EP1202736B1 (en) 1999-07-28 2008-09-17 The Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US20020155445A1 (en) 1999-12-16 2002-10-24 Jarvik Jonathan W. Methods and products for peptide based DNA sequence identification and analysis
AUPQ598300A0 (en) 2000-03-03 2000-03-23 Citrus Sensation Pty Ltd Citrus fruit preservative
US6576105B1 (en) 2000-03-31 2003-06-10 Truman State University Pteridine analysis by capillary electrophoresis using laser-induced fluorescence detection
US6784178B2 (en) 2000-04-12 2004-08-31 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US6544994B2 (en) 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
AU2001280215B9 (en) 2000-08-31 2007-03-22 Asubio Pharma Co., Ltd. Process for Production of Biopterin Compound
DE10043845A1 (en) 2000-09-06 2002-03-14 Gruenenthal Gmbh Method of measuring NO synthase activity
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
UA80393C2 (en) 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
US6537992B2 (en) 2001-01-05 2003-03-25 John D. Parker Regulation of organic nitrate tolerance
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US6693094B2 (en) 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US6500857B1 (en) 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions
US20030004125A1 (en) 2001-06-22 2003-01-02 Hirst David G. Inducible gene
US20030078231A1 (en) 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
US6787178B2 (en) * 2001-07-09 2004-09-07 Kiyoshi Yamamoto Health drink and method for production thereof
JP4082888B2 (en) 2001-10-17 2008-04-30 広栄化学工業株式会社 Process for producing biaryl compounds
CH696628A5 (en) * 2002-02-26 2007-08-31 Eprova Ag Use of folate suitable for the manufacture of a preparation for the prevention and treatment of inflammation and inflammation-associated diseases, in particular for influencing the
DE10260263A1 (en) 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Use of tetrahydrobiopterin derivatives for the treatment and nutrition of patients with amino acid metabolism disorders
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
US20070167353A1 (en) 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
WO2005049614A2 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
US7067659B2 (en) 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
WO2005107759A1 (en) 2004-05-11 2005-11-17 Daiichi Asubo Pharma Co., Ltd. Bh4-responsive hyperphenylalaninemia remedies
JP2008504295A (en) 2004-06-25 2008-02-14 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalaninemia
KR20070084270A (en) * 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. Stable tablet formulation
EP1819340A2 (en) 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US20060194808A1 (en) 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate
JP2009518415A (en) 2005-12-05 2009-05-07 バイオマリン ファーマシューティカル インコーポレイテッド Methods and compositions for treatment of disease
WO2007072911A1 (en) 2005-12-22 2007-06-28 Asubio Pharma Co., Ltd. Preparation with improved bioabsorbability of sapropterin hydrochloride
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
EP3539560A1 (en) 2007-02-22 2019-09-18 Children's Hospital & Research Center at Oakland Fatty acid formulations and methods of use thereof
JP5226960B2 (en) * 2007-02-28 2013-07-03 株式会社スクウェア・エニックス GAME DEVICE, VIRTUAL CAMERA CONTROL METHOD, PROGRAM, AND RECORDING MEDIUM

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63267781A (en) * 1987-04-24 1988-11-04 Suntory Ltd Remedy for ameliorating neutral symptom accompanying to malignant tumor and grave viral infection
EP0906913A1 (en) * 1997-10-06 1999-04-07 Ernst Werner Pteridinderivatives as NO synthase inhibitors
WO2005065018A2 (en) * 2003-11-17 2005-07-21 Merck Eprova Ag Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELZAOUK LINA ET AL: "Dwarfism and low insulin-like growth factor-1 due to dopamine depletion in Pts-/- mice rescued by feeding neurotransmitter precursors and H4-biopterin.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 30, 25 July 2003 (2003-07-25), pages 28303 - 28311, XP002392001, ISSN: 0021-9258 *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 079 (C - 571) 22 February 1989 (1989-02-22) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Also Published As

Publication number Publication date
AU2005306686A1 (en) 2006-05-26
CA2581814C (en) 2015-10-13
PE20061294A1 (en) 2006-12-18
TW200624120A (en) 2006-07-16
IL182161A0 (en) 2007-07-24
AR052238A1 (en) 2007-03-07
BRPI0517088A (en) 2008-09-30
US20080207626A1 (en) 2008-08-28
US7566462B2 (en) 2009-07-28
CN101132776A (en) 2008-02-27
US20070270581A1 (en) 2007-11-22
JP2014012740A (en) 2014-01-23
IL182161A (en) 2011-08-31
CA2581814A1 (en) 2006-05-26
MX2007005039A (en) 2007-06-19
JP2008520574A (en) 2008-06-19
US8003126B2 (en) 2011-08-23
EP1845952A2 (en) 2007-10-24
EP2436379A1 (en) 2012-04-04
KR20070084270A (en) 2007-08-24
MY142120A (en) 2010-09-15
WO2006055511A2 (en) 2006-05-26
AU2005306686B2 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
WO2006055511A3 (en) Stable tablet formulation of tetrahydrobiopterin
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2007025540A3 (en) Substituted imidazo[1,2b]pyridazines as kinase inhibitors, the production thereof, and use of the same as medicaments
WO2006086562A3 (en) Phenylazetidinone derivatives
RS50812B (en) Dry granulated composition comprising emtricitabine and tenofovir df
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2006131591A3 (en) An entacapone-containing oral dosage form
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2004112719A8 (en) Chemical compounds
WO2005046603A3 (en) Pyridine compounds
WO2006018184A3 (en) Spirocyclic cyclohexane derivatives
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
WO2007015923A3 (en) Benzimidazoles useful as inhibitors of protein kinases
WO2006023843A3 (en) Novel heterocycles
WO2006091836A8 (en) Formulations of ladostigil tartrate
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2006060542A3 (en) Formulations of substituted benzoxazoles
WO2004087700A8 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
WO2006091847A3 (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
WO2006105482A3 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580038910.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005306686

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2581814

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 182161

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2764/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005822282

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005306686

Country of ref document: AU

Date of ref document: 20051116

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005306686

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005039

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007541419

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020077011104

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10563418

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005822282

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10563418

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0517088

Country of ref document: BR